The market turbulence unleashed by President Donald Trump’s tariff policies will likely evaporate the trickle of biotech IPOs ...

Bank of America Securities analyst Tim Anderson reiterated a Buy rating on Metsera, Inc. (MTSR – Research Report) today and set a price target ...

Despite several big deals that buoyed the numbers, North America early- and seed-stage investment declined to multiquarter ...

Wall Street on Friday suffered its biggest weekly retreat since the peak of the COVID-19 pandemic collapse in 2020. The panic ...

Oral semaglutide, already approved for type 2 diabetes, led to a reduction in CV events in patients with established atherosclerotic disease, CKD, or both.

Equities research analysts at Cantor Fitzgerald reduced their FY2025 earnings per share estimates for Metsera in a report issued on Thursday, March 27th. Cantor Fitzgerald analyst P. Agrawal now ...

Oral semaglutide reduced risk for major adverse CV events by 14% in high-risk adults with type 2 diabetes regardless of SGLT2 inhibitor use, according to data presented at the American College of ...

After an IPO this year, Metsera is making its best effort to catch up to obesity drug giants Eli Lilly and Novo Nordisk.

"2024 was a year of exceptional execution and acceleration at Metsera," said Whit Bernard, Chief Executive Officer of Metsera. "We advanced MET-097i, our monthly, fully-biased GLP-1 RA injectable ...

“2024 was a year of exceptional execution and acceleration at Metsera,” said Whit Bernard, Chief Executive Officer of Metsera.“We advanced MET-097i, our monthly, fully-biased GLP-1 RA ...